Kavitha Thilak - Academia.edu (original) (raw)
Papers by Kavitha Thilak
International journal of medicine, Feb 22, 2024
Transfusion Medicine is a multidisciplinary field that deals with the collection, testing, proces... more Transfusion Medicine is a multidisciplinary field that deals with the collection, testing, processing, storing, and transfusing of blood and blood components in the treatment of human diseases. Pre-analytical errors, misidentification, and mistransfusion are all regarded as major impediments and risks in safe blood transfusion practices. 1 Several incidents have been documented worldwide during the collection, transport, storage, and transfusion of blood. Human errors during the process of blood collection to blood transfusion are a life-threatening issue. In order to reduce errors and ensure safety, blood transfusion. Following proper guidelines and protocols, along with use of technology which helps to reduce human generated errors in blood transfusion process. Traditional blood transfusion practise in many institutions includes a lot of manual stages with a significant potential of error. Hospitals and blood banks now require modern and innovative systems that provide high levels of accuracy, traceability, automation, and reliability to assure ultimate quality of services. In order to ensure quality blood transfusion implementation of technologies, including block chain technology, machine learning, AI, artificial neural networks, algorithm-based learning and introduction of RFID and IoT. Transfusion medicine is still in its early stages of technological adoption; data loss, patient data privacy, cost effectiveness, remain issues. In this paper, we discuss current updates on introducing technology in transfusion services, future advances in transfusion medicine, and how these technologies can reduce errors, retrieve data, predict demand for blood, reduce blood wastage and manage blood storage, manage workload, and ensure transfusion safety. Aim Aim of the study is to check the current status, future advances and limitations of modern technology in transfusion services including blockchain technology, machine learning, AI, artificial neural networks, algorithm-based learning and introducing RFID and IoT.
International journal of science and research, Mar 5, 2023
International Journal of Science and Research (IJSR) ISSN: 2319-7064, 2023
Reticulated platelets are immature platelets circulating in blood; they reflect the activity of m... more Reticulated platelets are immature platelets circulating in blood; they reflect the activity of megakaryopoiesis in the bone marrow. Therefore, they can be used as a non-invasive test in patients with thrombocytopenia in various clinical conditions. Reticulated or immature platelet assays are useful for the differential diagnosis of thrombocytopenia and for monitoring bone marrow recovery after chemotherapy or stem cell transplantation and several other clinical entities. The concentration of retPLT in bone marrow is on the average 2-3 times higher than in peripheral blood, where they correlate with megakaryocyte numbers. The platelets persist in the circulation for 7-10 days, retPLT have a much shorter lifespan (< 1 day). Therefore they can act as a marker of megakaryopoietic activity in the bone marrow which gives retPLT clinical and diagnostic utility. This review provides an overview of the clinical conditions in which reticulated platelets or immature platelets can be considered as a diagnostic tool or prognostic tool. This overview also indicates that more research is needed before reticulated or immature platelet assays can be applied in other clinical conditions than thrombocytopenia and after transplantation.
IOSR
Hemophilia is a rare X-linked bleeding disorder caused by a deficiency of coagulation factors Fac... more Hemophilia is a rare X-linked bleeding disorder caused by a deficiency of coagulation factors Factor VIII and Factor IX. Hemophilia can also be acquired due to autoimmune antibodies developed against factor VIII and factor IX. Management of acute bleeding mainly by coagulation factor replacement therapy is the core stone treatment of hemophilia. Development of antibodies(inhibitors) against FVIII or FIX concentrates is a major complication. Hemophilia replacement therapy requires extensive time period and constant monitoring of patients on factor levels, development of inhibitors,etc. Many researches and clinical trials are ongoing in order to develop a cost effective single dose therapeutic product which can offer a permanent recovery. The creation of gene therapy is a recent invention. In order to introduce a copy of the gene that codes for the clotting factor that is missing in people with hemophilia, modified viruses such adeno-associated virus and lentivirus (which do not cause disease) are used as a vector. Following treatments,patients produce their own coagulation factors normally after receiving viral treatment. A single intravenous administration may lead to long-term expression of FVIII/FIX, maintenance of steady-state plasma concentrations, and reduction (or perhaps eradication) of bleeding episodes over the course of the recipient's lifetime. Clinical trials have evaluated several gene treatments, with promising results. However, there are major obstacles to overcome, includingimmunogenicity towards viral vectors, hepatotoxicity, cost and affordability of new genetic products. This literature review includes reviewing a summary of some of the research in the advances of gene therapy, limitations, future perspectives, and other advances in hemophilia therapy including Platelet-Targeted FVIII Gene Therapy, RNAi therapeutic targeting antithrombin, placental cell-based gene therapy,Non-Gene Therapy bi-specific antibodies, etc. Methodology: The information is collected from secondary sources published in various scholarly journals selected from google scholar. The research articles systematically reviews advances, limitations, future perspectives, and other advances in hemophilia therapy. Results/Findings: Based on a systematic review, advances in gene therapy, limitations, future perspectives, and other advances in hemophilia therapy are identified. Many of clinical trials have evaluated several gene treatments, with promising results. Considering the rapid developments in hemophilia gene therapy clinical trials, there is a critical need for education to prepare the hemophilia care team for the potential integration of gene therapy into the therapeutic options available to those with the condition.More studies in the field will help to overcome current challenges in hemophilia therapy, expectingcost-effective, productive, less immunogenic gene therapy products to be approved and available in markets soon.
International journal of medicine, Feb 22, 2024
Transfusion Medicine is a multidisciplinary field that deals with the collection, testing, proces... more Transfusion Medicine is a multidisciplinary field that deals with the collection, testing, processing, storing, and transfusing of blood and blood components in the treatment of human diseases. Pre-analytical errors, misidentification, and mistransfusion are all regarded as major impediments and risks in safe blood transfusion practices. 1 Several incidents have been documented worldwide during the collection, transport, storage, and transfusion of blood. Human errors during the process of blood collection to blood transfusion are a life-threatening issue. In order to reduce errors and ensure safety, blood transfusion. Following proper guidelines and protocols, along with use of technology which helps to reduce human generated errors in blood transfusion process. Traditional blood transfusion practise in many institutions includes a lot of manual stages with a significant potential of error. Hospitals and blood banks now require modern and innovative systems that provide high levels of accuracy, traceability, automation, and reliability to assure ultimate quality of services. In order to ensure quality blood transfusion implementation of technologies, including block chain technology, machine learning, AI, artificial neural networks, algorithm-based learning and introduction of RFID and IoT. Transfusion medicine is still in its early stages of technological adoption; data loss, patient data privacy, cost effectiveness, remain issues. In this paper, we discuss current updates on introducing technology in transfusion services, future advances in transfusion medicine, and how these technologies can reduce errors, retrieve data, predict demand for blood, reduce blood wastage and manage blood storage, manage workload, and ensure transfusion safety. Aim Aim of the study is to check the current status, future advances and limitations of modern technology in transfusion services including blockchain technology, machine learning, AI, artificial neural networks, algorithm-based learning and introducing RFID and IoT.
International journal of science and research, Mar 5, 2023
International Journal of Science and Research (IJSR) ISSN: 2319-7064, 2023
Reticulated platelets are immature platelets circulating in blood; they reflect the activity of m... more Reticulated platelets are immature platelets circulating in blood; they reflect the activity of megakaryopoiesis in the bone marrow. Therefore, they can be used as a non-invasive test in patients with thrombocytopenia in various clinical conditions. Reticulated or immature platelet assays are useful for the differential diagnosis of thrombocytopenia and for monitoring bone marrow recovery after chemotherapy or stem cell transplantation and several other clinical entities. The concentration of retPLT in bone marrow is on the average 2-3 times higher than in peripheral blood, where they correlate with megakaryocyte numbers. The platelets persist in the circulation for 7-10 days, retPLT have a much shorter lifespan (< 1 day). Therefore they can act as a marker of megakaryopoietic activity in the bone marrow which gives retPLT clinical and diagnostic utility. This review provides an overview of the clinical conditions in which reticulated platelets or immature platelets can be considered as a diagnostic tool or prognostic tool. This overview also indicates that more research is needed before reticulated or immature platelet assays can be applied in other clinical conditions than thrombocytopenia and after transplantation.
IOSR
Hemophilia is a rare X-linked bleeding disorder caused by a deficiency of coagulation factors Fac... more Hemophilia is a rare X-linked bleeding disorder caused by a deficiency of coagulation factors Factor VIII and Factor IX. Hemophilia can also be acquired due to autoimmune antibodies developed against factor VIII and factor IX. Management of acute bleeding mainly by coagulation factor replacement therapy is the core stone treatment of hemophilia. Development of antibodies(inhibitors) against FVIII or FIX concentrates is a major complication. Hemophilia replacement therapy requires extensive time period and constant monitoring of patients on factor levels, development of inhibitors,etc. Many researches and clinical trials are ongoing in order to develop a cost effective single dose therapeutic product which can offer a permanent recovery. The creation of gene therapy is a recent invention. In order to introduce a copy of the gene that codes for the clotting factor that is missing in people with hemophilia, modified viruses such adeno-associated virus and lentivirus (which do not cause disease) are used as a vector. Following treatments,patients produce their own coagulation factors normally after receiving viral treatment. A single intravenous administration may lead to long-term expression of FVIII/FIX, maintenance of steady-state plasma concentrations, and reduction (or perhaps eradication) of bleeding episodes over the course of the recipient's lifetime. Clinical trials have evaluated several gene treatments, with promising results. However, there are major obstacles to overcome, includingimmunogenicity towards viral vectors, hepatotoxicity, cost and affordability of new genetic products. This literature review includes reviewing a summary of some of the research in the advances of gene therapy, limitations, future perspectives, and other advances in hemophilia therapy including Platelet-Targeted FVIII Gene Therapy, RNAi therapeutic targeting antithrombin, placental cell-based gene therapy,Non-Gene Therapy bi-specific antibodies, etc. Methodology: The information is collected from secondary sources published in various scholarly journals selected from google scholar. The research articles systematically reviews advances, limitations, future perspectives, and other advances in hemophilia therapy. Results/Findings: Based on a systematic review, advances in gene therapy, limitations, future perspectives, and other advances in hemophilia therapy are identified. Many of clinical trials have evaluated several gene treatments, with promising results. Considering the rapid developments in hemophilia gene therapy clinical trials, there is a critical need for education to prepare the hemophilia care team for the potential integration of gene therapy into the therapeutic options available to those with the condition.More studies in the field will help to overcome current challenges in hemophilia therapy, expectingcost-effective, productive, less immunogenic gene therapy products to be approved and available in markets soon.